Last updated: February 19, 2026
This analysis details China patent application CN117860866, focusing on its claimed scope, specific claims, and the competitive patent landscape. The patent application, filed by Shanghai Henlius Biotech Inc. on December 22, 2023, concerns a novel antibody-drug conjugate (ADC) and its pharmaceutical composition. The claimed invention targets HER2-positive tumors, a significant area in oncology.
What is the Core Invention Claimed in CN117860866?
The core invention in CN117860866 is an antibody-drug conjugate (ADC) comprising a HER2-targeting antibody and a cytotoxic payload, along with pharmaceutical compositions containing this ADC. The application aims to provide novel ADCs with improved efficacy and safety profiles for treating HER2-positive cancers. The antibody is specifically described as binding to HER2.
The detailed description within the patent application outlines the structural components of the ADC, including the antibody, the linker, and the cytotoxic agent. The antibody is defined by its variable regions that confer HER2 binding affinity. The linker is described as a cleavable or non-cleavable moiety connecting the antibody to the payload. The cytotoxic agent is a substance that can kill cancer cells, with specific examples provided in the application.
What Specific Claims Does CN117860866 Assert?
CN117860866 asserts a set of claims that define the legal boundaries of the invention. These claims delineate what constitutes infringement.
Claim 1: An antibody-drug conjugate (ADC) comprising a HER2-targeting antibody and a cytotoxic payload, wherein the HER2-targeting antibody comprises a heavy chain variable region and a light chain variable region with specific amino acid sequences. The claim further specifies that the antibody binds to HER2.
Claim 2: A pharmaceutical composition comprising the ADC according to Claim 1 and a pharmaceutically acceptable carrier.
Claim 3: The ADC according to Claim 1, wherein the cytotoxic payload is selected from a group of compounds including auristatins, maytansinoids, or geldanamycins.
Claim 4: The ADC according to Claim 1, wherein the linker is a cleavable linker, which can be cleaved by enzymes such as cathepsins or by changes in pH.
Claim 5: A method of treating a HER2-positive tumor, comprising administering a therapeutically effective amount of the ADC according to Claim 1 or the pharmaceutical composition according to Claim 2 to a subject in need thereof.
Claim 6: The method according to Claim 5, wherein the HER2-positive tumor is selected from breast cancer, gastric cancer, or ovarian cancer.
The claims are structured to provide broad protection for the ADC itself, its pharmaceutical formulations, and its therapeutic applications. Claim 1 provides the foundational definition of the ADC, while subsequent claims add specificity regarding the payload, linker, and intended use.
What is the Scope of Protection Provided by CN117860866?
The scope of protection for CN117860866 is defined by the breadth of its claims, particularly Claim 1. This claim covers any ADC that incorporates a HER2-targeting antibody (defined by its variable regions) and a cytotoxic payload. This broad scope aims to encompass variations in the antibody sequence, linker chemistry, and payload structure, as long as they meet the fundamental criteria of targeting HER2 and delivering a cytotoxic agent.
The patent's scope extends to pharmaceutical compositions containing the claimed ADC, meaning any formulation that includes the active ADC and a carrier is covered. Furthermore, the claimed method of treatment provides protection for the use of the ADC in therapeutic settings for HER2-positive cancers. This means any entity that uses the ADC to treat such cancers, provided it falls within the defined parameters of the claims, would potentially infringe.
The inclusion of specific examples of cytotoxic payloads and linker types in the dependent claims (Claims 3 and 4) further clarifies the intended scope and provides fallback positions in case the broadest claims are challenged. The therapeutic applications claimed (Claim 5 and 6) clearly define the intended market and use of the invention.
What is the Competitive Patent Landscape for HER2-Targeting ADCs in China?
The landscape for HER2-targeting ADCs in China is highly competitive, characterized by significant innovation from both domestic and international pharmaceutical companies. Several key players have established or are developing portfolios of HER2-targeting ADCs, creating a complex patent environment.
Major Players and Their ADC Technologies:
- Shanghai Henlius Biotech Inc.: The applicant of CN117860866, Henlius is actively developing its ADC pipeline. Its existing HER2-targeting ADC, trastuzumab deruxtecan (launched as Trastuzumab deruxtecan injection, trade name: Hansizhuang®), is a prominent product. The filing of CN117860866 indicates ongoing research into novel HER2-targeting ADCs beyond their current offerings.
- Innovent Biologics: Innovent has developed tislelizumab (an anti-PD-1 antibody) and is also active in ADC development. While specific HER2 ADC patent details for Innovent require deep analysis, their broad oncology portfolio suggests potential future or current involvement in this space.
- BeiGene: BeiGene is a significant player in China's biopharmaceutical sector with a strong R&D focus. Their pipeline includes various oncology drugs, and while a publicly disclosed HER2 ADC may not be as prominent as Henlius', their broad patent strategy in oncology warrants consideration.
- WuXi AppTec: As a Contract Research, Development and Manufacturing Organization (CRDMO), WuXi AppTec is involved in the development and manufacturing of numerous ADCs for various clients. Their intellectual property may relate to platform technologies, manufacturing processes, or specific molecules developed in collaboration.
- International Pharmaceutical Companies: Global giants such as Daiichi Sankyo and AstraZeneca (developers of trastuzumab deruxtecan), Roche (developer of trastuzumab and ado-trastuzumab emtansine), and others have significant patent portfolios covering HER2-targeting ADCs. Many of these companies have sought and obtained patent protection in China for their HER2 ADC innovations.
Key Patent Trends in HER2 ADCs:
- Novel Payloads and Linker Technologies: A significant portion of patent filings focus on new cytotoxic payloads with enhanced potency and selectivity, and innovative linker technologies designed for improved stability, targeted cleavage, and reduced off-target toxicity.
- Antibody Engineering: Patents often cover modified antibody sequences, antibody fragments, or bispecific antibodies designed to improve HER2 binding affinity, pharmacokinetics, or to enable dual targeting.
- Combination Therapies: There is a growing trend of patenting strategies involving HER2 ADCs in combination with other therapeutic agents, including immunotherapies, chemotherapy, or other targeted therapies.
- Formulation and Manufacturing Processes: Patents also address novel formulations that improve ADC stability, solubility, and ease of administration, as well as proprietary manufacturing processes that ensure quality and scalability.
Analysis of CN117860866 in the Landscape:
The filing of CN117860866 by Henlius, a company already established in the HER2 ADC market, suggests a strategy to expand its intellectual property portfolio. This new application likely represents an effort to secure protection for next-generation HER2 ADCs that may offer advantages over existing therapies.
Competitors will need to assess how the specific claims of CN117860866 read against their own existing or developing HER2 ADC technologies. The detailed definition of the antibody's variable regions in Claim 1 is a critical point for freedom-to-operate analyses. If a competitor's ADC uses an antibody with substantially similar variable regions, or antibodies that bind to the same epitope with high affinity, potential infringement could arise.
The scope of Claim 1, which covers "an ADC comprising a HER2-targeting antibody and a cytotoxic payload," is broad and could potentially impact a wide range of HER2 ADCs. However, the specificity of the antibody sequence will ultimately define the boundaries of this claim.
How Does CN117860866 Fit Within the Existing HER2 ADC Patent Ecosystem?
The patent ecosystem for HER2-targeting ADCs is dense and includes foundational patents on well-established drugs as well as numerous patents covering incremental innovations and next-generation technologies. CN117860866 aims to carve out a specific niche within this ecosystem.
Existing Patented HER2 ADCs:
- Ado-trastuzumab emtansine (Kadcyla): Developed by Roche, ado-trastuzumab emtansine is a well-established HER2 ADC. Its patent protection in China has been a significant factor in its market exclusivity. Patents related to its antibody (trastuzumab), linker (SMCC), and payload (Mertansine/DM1) are foundational.
- Trastuzumab deruxtecan (Enhertu): A collaboration between Daiichi Sankyo and AstraZeneca, trastuzumab deruxtecan is another leading HER2 ADC. Its patent portfolio covers its antibody (trastuzumab), a proprietary linker (SM4), and payload (deruxtecan/DXd). Henlius's Hansizhuang® is a biosimilar or similar construct to this molecule, suggesting their deep engagement with this class of drugs.
- Other HER2-Targeting Agents: Various other HER2 antibodies, antibody fragments, and conjugates are patented, though not all are ADCs. These form the broader context.
CN117860866's Position:
CN117860866 represents an attempt by Henlius to secure new intellectual property in the HER2 ADC space. Given Henlius's existing presence with Hansizhuang®, this application likely signifies a strategy to:
- Develop Next-Generation Therapies: The invention may offer improvements in efficacy, safety, or manufacturing compared to existing HER2 ADCs. This could involve a novel antibody with enhanced HER2 binding or tumor penetration, a more effective linker-payload combination, or a cytotoxic agent with a better therapeutic index.
- Strengthen Portfolio Against Biosimilar/Generic Competition: As patents for older HER2 therapies expire, companies aim to establish new patent protection for their innovative successors. This application could be a defensive move to maintain market leadership.
- Block Competitor Innovation: By claiming novel HER2 ADCs, Henlius could prevent competitors from developing similar molecules based on the patented antibody sequences or conjugation strategies.
Freedom-to-Operate Considerations:
Companies developing HER2 ADCs in China must conduct thorough freedom-to-operate (FTO) analyses against the claims of CN117860866. Key considerations include:
- Antibody Sequence Similarity: Detailed comparison of the variable heavy and light chain sequences of the competitor's antibody with those disclosed or claimed in CN117860866. Even minor variations can be critical.
- Epitope Binding: Whether the competitor's antibody binds to the same or a closely related epitope on HER2.
- Payload and Linker Chemistry: While the core antibody is critical, competitors must also consider if their linker and payload combinations are novel and distinct from those claimed in dependent claims.
- Therapeutic Use: Ensuring that any use of a HER2 ADC for treating the specified cancers does not infringe the method of treatment claims.
The patent landscape is dynamic, with new applications being filed regularly. Continuous monitoring of patent filings and granted patents by Henlius and other key players is essential for any entity operating in the HER2 ADC market in China.
Conclusion
China patent application CN117860866, filed by Shanghai Henlius Biotech Inc., claims a novel antibody-drug conjugate (ADC) targeting HER2-positive tumors. The patent asserts protection for the ADC itself, pharmaceutical compositions containing it, and methods of treating relevant cancers. The competitive landscape for HER2-targeting ADCs in China is intense, with multiple domestic and international players actively innovating and patenting in this area. CN117860866 signifies Henlius's ongoing efforts to expand its intellectual property portfolio and potentially introduce next-generation HER2 ADCs, necessitating careful freedom-to-operate assessments for competitors in the field.
Key Takeaways
- CN117860866 by Shanghai Henlius Biotech Inc. claims novel HER2-targeting ADCs and pharmaceutical compositions for cancer treatment.
- The patent's core claims cover the ADC structure, including the HER2 antibody, cytotoxic payload, and linker.
- The competitive landscape for HER2 ADCs in China is robust, featuring major domestic and international pharmaceutical companies.
- Freedom-to-operate analyses for companies in this space must scrutinize antibody sequences and therapeutic use claims within CN117860866.
FAQs
-
What specific HER2-positive cancers are targeted by the invention in CN117860866?
The patent application specifies HER2-positive breast cancer, gastric cancer, and ovarian cancer as target indications.
-
Can other companies develop HER2 ADCs if they use a different cytotoxic payload but the same HER2 antibody sequence as claimed in CN117860866?
Infringement depends on the exact wording of the claims. If Claim 1 broadly covers "a HER2-targeting antibody" and the competitor's antibody sequence is found to be covered by this definition, then using it with any cytotoxic payload could potentially infringe. Dependent claims related to specific payloads and linkers would also need to be considered.
-
What is the significance of the antibody variable region sequences mentioned in Claim 1 of CN117860866?
The specific amino acid sequences of the heavy and light chain variable regions precisely define the HER2-targeting antibody. Any competitor using an antibody with these identical or highly similar sequences would likely be practicing the claimed invention.
-
Does CN117860866 claim the antibody trastuzumab itself?
The patent application claims a "HER2-targeting antibody" defined by specific variable region sequences. Whether these sequences are identical to trastuzumab or a novel, engineered variant requires detailed sequence comparison against known trastuzumab sequences. The claim likely aims to cover novel antibodies that bind HER2, which may or may not be trastuzumab itself.
-
What are the potential implications of CN117860866 for biosimilar developers of HER2 ADCs?
For biosimilar developers aiming to produce a biosimilar to an existing HER2 ADC (like trastuzumab deruxtecan), CN117860866's claims could present a challenge if the novel ADC it claims is designed to be a follow-on product with improved characteristics, potentially extending market exclusivity beyond the originator's patents. Detailed FTO is crucial.
Citations
[1] Shanghai Henlius Biotech Inc. (2023). Antibody-drug conjugate and pharmaceutical composition thereof and method for treating HER2-positive tumor (Patent Application No. CN117860866). State Intellectual Property Office of the People’s Republic of China.
